Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Cullinan Oncology, Inc. have bought $0 and sold $3.64M worth of Cullinan Oncology, Inc. stock.
On average, over the past 5 years, insiders at Cullinan Oncology, Inc. have bought $19.31M and sold $11.49M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,090 shares for transaction amount of $100,316 was made by AHMED NADIM (President and CEO) on 2022‑06‑06.
2024-05-07 | Sale | Michaelson Jennifer | Chief Scientific Officer | 5,606 0.0138% | $30.06 | $168,516 | -22.09% | |
2024-05-06 | Sale | Michaelson Jennifer | Chief Scientific Officer | 58,000 0.1331% | $28.07 | $1.63M | -19.33% | |
2024-02-01 | Sale | Savill Corrine | Chief Business Officer | 40,000 0.104% | $16.18 | $647,200 | +3.26% | |
2024-01-29 | Sale | Savill Corrine | Chief Business Officer | 40,000 0.0901% | $14.09 | $563,600 | +22.95% | |
2024-01-23 | Sale | Savill Corrine | Chief Business Officer | 21,316 0.0493% | $12.46 | $265,597 | +43.08% | |
2024-01-22 | Sale | Savill Corrine | Chief Business Officer | 18,684 0.0431% | $12.14 | $226,911 | +46.66% | |
2023-12-26 | Sale | AHMED NADIM | President and CEO | 4,272 0.0096% | $9.24 | $39,473 | +82.52% | |
2023-12-21 | Sale | Michaelson Jennifer | Chief Scientific Officer | 1,145 0.0024% | $8.50 | $9,733 | +84.28% | |
2023-12-21 | Sale | Trigilio Jeffrey | Chief Financial Officer | 1,920 0.004% | $8.50 | $16,320 | +84.28% | |
2023-12-21 | Sale | Jones Jeffrey Alan | Chief Medical Officer | 1,860 0.0039% | $8.50 | $15,810 | +84.28% | |
2023-12-21 | Sale | SUMER JACQUELYN L | Chief Legal Officer | 1,400 0.0029% | $8.50 | $11,900 | +84.28% | |
2023-12-18 | Sale | Michaelson Jennifer | Chief Scientific Officer | 238 0.0005% | $8.22 | $1,956 | +92.63% | |
2023-12-18 | Sale | Trigilio Jeffrey | Chief Financial Officer | 398 0.0008% | $8.22 | $3,272 | +92.63% | |
2023-12-18 | Sale | Jones Jeffrey Alan | Chief Medical Officer | 386 0.0008% | $8.22 | $3,173 | +92.63% | |
2023-12-18 | Sale | SUMER JACQUELYN L | Chief Legal Officer | 290 0.0006% | $8.22 | $2,384 | +92.63% | |
2023-12-12 | Sale | Michaelson Jennifer | Chief Scientific Officer | 1,068 0.0025% | $7.81 | $8,341 | +120.67% | |
2023-12-12 | Sale | Trigilio Jeffrey | Chief Financial Officer | 1,926 0.0045% | $7.81 | $15,042 | +120.67% | |
2023-06-28 | Sale | AHMED NADIM | President and CEO | 759 0.0019% | $11.40 | $8,653 | -3.47% | |
2023-06-20 | Sale | Michaelson Jennifer | Chief Development Officer | 238 0.0006% | $12.94 | $3,080 | -16.68% | |
2023-06-20 | Sale | Trigilio Jeffrey | Chief Financial Officer | 399 0.001% | $12.94 | $5,163 | -16.68% |
Savill Corrine | Chief Business Officer | 165990 0.388% | $16.50 | 0 | 6 | |
AHMED NADIM | President and CEO | 111550 0.2607% | $16.50 | 1 | 5 | <0.0001% |
Michaelson Jennifer | Chief Scientific Officer | 129582 0.2047% | $16.50 | 0 | 20 | |
Trigilio Jeffrey | Chief Financial Officer | 83919 0.1962% | $16.50 | 1 | 12 | <0.0001% |
Jones Jeffrey Alan | Chief Medical Officer | 56191 0.1313% | $16.50 | 0 | 6 | |
SUMER JACQUELYN L | Chief Legal Officer | 44133 0.1032% | $16.50 | 0 | 6 | |
UBS Oncology Impact Fund L.P. | 10 percent owner | 7648268 17.8779% | $16.50 | 1 | 18 | <0.0001% |
LAMPERT MARK N | 4058854 9.4876% | $16.50 | 3 | 0 | +15.29% | |
Jovan-Embiricos Morana | 1281952 2.9966% | $16.50 | 1 | 3 | <0.0001% | |
Hughes Owen | President and CEO | 506226 1.1833% | $16.50 | 1 | 0 | <0.0001% |
GADICKE ANSBERT | 244551 0.5716% | $16.50 | 1 | 18 | <0.0001% | |
Zawel Leigh | See Remarks | 37285 0.0872% | $16.50 | 0 | 7 | |
Baeuerle Patrick | See Remarks | 0 0% | $16.50 | 0 | 2 |
Bioimpact Capital Llc | $130.33M | 13.27 | 7.65M | 0% | +$0 | 21.09 | |
Bvf Inc Il | $54.47M | 5.55 | 3.2M | 0% | +$0 | 0.4 | |
Blue Owl Capital Holdings Lp | $49.84M | 5.08 | 2.92M | -14.47% | -$8.43M | 9.38 | |
Franklin Templeton Investments | $45.95M | 4.68 | 2.7M | -17.81% | -$9.96M | 0.01 | |
BlackRock | $41.39M | 4.21 | 2.43M | -1.35% | -$567,108.26 | <0.01 | |
The Vanguard Group | $30.23M | 3.08 | 1.77M | +0.16% | +$49,450.08 | <0.01 | |
State Street | $24.29M | 2.47 | 1.43M | +152.11% | +$14.66M | <0.01 | |
Paradigm BioCapital Advisors LP | $22.97M | 2.34 | 1.35M | New | +$22.97M | 0.83 | |
Braidwell Lp | $21.14M | 2.15 | 1.24M | 0% | +$0 | 1.19 | |
Nextech Invest | $20.81M | 2.12 | 1.22M | 0% | +$0 | 3.39 | |
Morgan Stanley | $19.64M | 2 | 1.15M | +25.3% | +$3.97M | <0.01 | |
Deerfield Management | $19.4M | 1.98 | 1.14M | New | +$19.4M | 0.38 | |
Citadel Advisors LLC | $18.9M | 1.93 | 1.11M | -2.09% | -$404,154.72 | 0.01 | |
Dimensional Fund Advisors | $16.93M | 1.72 | 993,377 | +8.48% | +$1.32M | 0.01 | |
Adage Capital Partners Gp L L C | $16.19M | 1.65 | 950,000 | New | +$16.19M | 0.03 | |
Logos Global Management Lp | $11.93M | 1.22 | 700,000 | New | +$11.93M | 1.28 | |
Geode Capital Management | $11.54M | 1.18 | 677,330 | +3.3% | +$369,251.04 | <0.01 | |
Helm Capital Management LLC | $10.68M | 1.09 | 626,929 | 0% | +$0 | 0.32 | |
Tang Capital Management, LLC | $9.73M | 0.99 | 571,138 | -25.94% | -$3.41M | 0.04 | |
Deutsche Bank | $9.36M | 0.95 | 549,276 | +0.68% | +$62,911.68 | <0.01 | |
OrbiMed | $8.82M | 0.9 | 517,606 | -5% | -$464,203.67 | 0.18 | |
Ameriprise Financial | $7.16M | 0.73 | 420,217 | +665.13% | +$6.22M | <0.01 | |
Renaissance Technologies | $5.47M | 0.56 | 321,100 | +21.59% | +$971,565.44 | 0.01 | |
Northern Trust | $4.5M | 0.46 | 263,949 | -1.11% | -$50,659.91 | <0.01 | |
Affinity Asset Advisors | $4.41M | 0.45 | 258,588 | -13.8% | -$705,660.56 | 0.78 | |
Charles Schwab | $4.39M | 0.45 | 257,873 | +4.53% | +$190,302.72 | <0.01 | |
PFM Health Sciences | $4.36M | 0.44 | 255,967 | New | +$4.36M | 0.12 | |
Parkman Healthcare Partners Llc | $3.04M | 0.31 | 178,396 | -66.33% | -$5.99M | 0.38 | |
Goldman Sachs | $2.89M | 0.29 | 169,367 | +31.99% | +$699,526.16 | <0.01 | |
UBS | $2.84M | 0.29 | 166,740 | +18.44% | +$442,375.50 | <0.01 | |
Bank of America | $2.24M | 0.23 | 131,349 | -3% | -$69,233.52 | <0.0001 | |
Qube Research & Technologies | $1.96M | 0.2 | 115,112 | +1,581.45% | +$1.84M | <0.01 | |
Rafferty Asset Management Llc | $1.65M | 0.17 | 97,055 | New | +$1.65M | 0.01 | |
First Trust | $1.63M | 0.17 | 95,771 | +3.12% | +$49,347.82 | <0.01 | |
BNY Mellon | $1.61M | 0.16 | 94,240 | -4.81% | -$81,161.54 | <0.0001 | |
Nuveen | $1.59M | 0.16 | 93,222 | +5.55% | +$83,478.97 | <0.0001 | |
Citigroup | $1.46M | 0.15 | 85,574 | +709.59% | +$1.28M | <0.01 | |
Kennedy Capital Management Inc | $1.44M | 0.15 | 84,234 | -47.36% | -$1.29M | 0.03 | |
Algert Global LLC | $1.36M | 0.14 | 79,680 | +94.25% | +$658,889.06 | 0.05 | |
Wellington Management Company | $1.16M | 0.12 | 68,358 | New | +$1.16M | <0.0001 | |
D. E. Shaw & Co. | $1.05M | 0.11 | 61,621 | +25.96% | +$216,442.11 | <0.01 | |
Schonfeld Group | $1.02M | 0.1 | 60,074 | -57.39% | -$1.38M | 0.01 | |
Ubs Oconnor Llc | $1.01M | 0.1 | 59,352 | +9.2% | +$85,199.99 | 0.09 | |
American Century Investments | $974,313.00 | 0.1 | 57,178 | +37.94% | +$267,953.97 | <0.01 | |
Cubist Systematic Strategies | $952,336.00 | 0.1 | 55,888 | -1.82% | -$17,687.60 | 0.01 | |
Invesco | $807,815.00 | 0.08 | 47,407 | +346.27% | +$626,799.14 | <0.0001 | |
Marshall Wace | $801,630.00 | 0.08 | 47,044 | +40.96% | +$232,936.87 | <0.01 | |
RhumbLine Advisers | $795,794.00 | 0.08 | 46,702 | +2.13% | +$16,562.71 | <0.01 | |
Swiss National Bank | $788,952.00 | 0.08 | 46,300 | 0% | +$0 | <0.01 | |
Credit Suisse | $779,665.00 | 0.08 | 45,755 | +6.65% | +$48,615.11 | <0.01 |